Skip to content

Swedish Orphan Biovitrum AB (publ) Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Thu, Feb 4, 2027, after the market closes · estimates and history

Swedish Orphan Biovitrum AB (publ) · E.SOBI.ST · Sweden
Use symbol E.SOBI.ST in our API & Excel add-in to retrieve this data ↓
479.20
(-0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 25.53%

Swedish Orphan Biovitrum AB (publ) Forecast

Swedish Orphan Biovitrum AB (publ) short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 25.5% a year, a typical one-standard-deviation range is 461.97–496.43 over a week, 443.89–514.51 over a month and 356.87–601.53 over a year. (Signals as of 5 Nov 2026.)

Swedish Orphan Biovitrum AB (publ) Price Chart

MacroFinance.ai

Swedish Orphan Biovitrum AB (publ) Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Swedish Orphan Biovitrum AB (publ)
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Swedish Orphan Biovitrum AB (publ)
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Swedish Orphan Biovitrum AB (publ)
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Swedish Orphan Biovitrum AB (publ)
P/E
25.42x
Mid-range vs own history
QoQ −78.2%
YoY −99.7%
now 25.419922.69 low9,083 high
ⓘP/E As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Swedish Orphan Biovitrum AB (publ)
P/S
5.27x
Stretched vs own history
QoQ +0.2%
YoY +27.6%
now 5.26924.06 low5.62 high
ⓘP/S As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Swedish Orphan Biovitrum AB (publ)
P/B
3.71x
Stretched vs own history
QoQ −2.7%
YoY +16.1%
now 3.70923.05 low4.03 high
ⓘP/B As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Swedish Orphan Biovitrum AB (publ)
EV/EBITDA
13.40x
Mid-range vs own history
QoQ −0.1%
YoY +12.2%
now 13.410.75 low15.03 high
ⓘEV/EBITDA As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Swedish Orphan Biovitrum AB (publ)
EV/Sales
5.74x
Stretched vs own history
QoQ −0.9%
YoY +25.4%
now 5.74314.45 low6.25 high
ⓘEV/Sales As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Swedish Orphan Biovitrum AB (publ)
FCF Yield
4.3%
Mid-range vs own history
QoQ −4.0%
YoY −27.7%
now 4.32394.12 low7.05 high
ⓘFCF Yield As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Earnings Yield
3.9%
Mid-range vs own history
QoQ +358.4%
YoY +34,691.7%
now 3.93390.01 low4.41 high
ⓘEarnings Yield As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Market Cap
$168.5B
Highest in 5 years
QoQ +4.6%
YoY +46.5%
now 168457.8722113,045 low175,137 high
ⓘMarket Cap As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Swedish Orphan Biovitrum AB (publ)
Net Debt
$15.1B
Mid-range vs own history
QoQ −8.2%
YoY +20.7%
now 1514910,454 low18,121 high
ⓘNet Debt As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Net Debt / EBITDA
1.11x
Low vs own history
QoQ −11.3%
YoY −5.9%
now 1.10560.89 low1.5 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Current Ratio
0.99x
Mid-range vs own history
QoQ +13.3%
YoY −2.6%
now 0.99170.7 low1.02 high
ⓘCurrent Ratio As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Quick Ratio
0.65x
Mid-range vs own history
QoQ +17.8%
YoY −5.4%
now 0.64950.47 low0.69 high
ⓘQuick Ratio As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Debt / Equity
0.36x
Mid-range vs own history
QoQ −14.5%
YoY −5.8%
now 0.35570.3 low0.47 high
ⓘDebt / Equity As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Piotroski F-Score
7
Mid-range vs own history
QoQ +75.0%
YoY 0.0%
now 74 low7 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Swedish Orphan Biovitrum AB (publ)
Altman Z-Score
3.73
Strong vs own history
QoQ +14.9%
YoY +20.5%
now 3.73022.81 low3.83 high
ⓘAltman Z-Score As of 22 Nov 2026.See Swedish Orphan Biovitrum AB (publ) returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  17 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Swedish Orphan Biovitrum AB (publ), red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Swedish Orphan Biovitrum AB (publ) fundamentals: income statement, balance sheet & cash flow

Swedish Orphan Biovitrum AB (publ) reported revenue of 28.24bn SEK and net income of 478.0m SEK in FY2025, the year ended 31 December 2025 — revenue up 8.5% and net income down 87.7% on the prior year. Free cash flow was 8.52bn SEK. These figures are as reported in the filings, not restated: 24 fiscal years and 71 quarters of history, back to December 2002.

Revenue (FY2025)
28.24bn SEK
+8.5%
Net income
478.0m SEK
-87.7%
Gross margin
43.63%
Free cash flow
8.52bn SEK
+94.5%
Net debt
10.45bn SEK
Swedish Orphan Biovitrum AB (publ) income statement, annual, as reported · SEK billions unless stated
SEK billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue28.2426.0322.1218.7915.53
Cost of revenue15.925.7912.184.813.48
Gross profit12.3220.249.9513.9812.05
Research & development3.253.542.802.351.99
Selling, general & admin.1.02—3.097.856.29
Operating income8.055.634.073.813.73
EBITDA10.969.307.236.055.72
Interest expense0.831.241.110.460.42
Pre-tax income0.034.412.953.323.30
Income tax-0.440.530.550.680.62
Net income0.483.892.412.642.68

Download Swedish Orphan Biovitrum AB (publ) fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.SOBI.ST&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 24 fiscal years and 71 quarters, the filing vintages behind each number and API access.
Create free account

Figures in SEK, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on Swedish Orphan Biovitrum AB (publ)

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Swedish Orphan Biovitrum AB (publ) Trading Strategies

9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Swedish Orphan Biovitrum AB (publ); 1 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

Explore all strategies →

Statistical Distribution of Returns

Plus

How Swedish Orphan Biovitrum AB (publ)’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Swedish Orphan Biovitrum AB (publ) behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Swedish Orphan Biovitrum AB (publ) (Sweden)

Swedish Orphan Biovitrum AB (publ) is a listed security in Sweden. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Swedish Orphan Biovitrum AB (publ)?
Swedish Orphan Biovitrum AB (publ) is a listed security in Sweden. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Swedish Orphan Biovitrum AB (publ) price?
The latest close is 479.2 (5 Nov 2026), -0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Swedish Orphan Biovitrum AB (publ) in an uptrend?
As of 5 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Swedish Orphan Biovitrum AB (publ)?
20-day realised volatility is 25.5% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 7.4% over a month and 3.6% over a week.
What factors affect Swedish Orphan Biovitrum AB (publ)?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Swedish Orphan Biovitrum AB (publ), grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Swedish Orphan Biovitrum AB (publ)?
9 backtested tactical asset allocation strategies trade Swedish Orphan Biovitrum AB (publ) through VGK; 1 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Swedish Orphan Biovitrum AB (publ) returns analysed?
The Statistical Distribution of Returns section shows the distribution of Swedish Orphan Biovitrum AB (publ) daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Swedish Orphan Biovitrum AB (publ) historical data?
In the Free historical data section of this page: the last 10 years of Swedish Orphan Biovitrum AB (publ) daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Swedish Orphan Biovitrum AB (publ) historical data (last 10 years)

Browse or instantly download the last 10 years of Swedish Orphan Biovitrum AB (publ) daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.SOBI.ST&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20464
2026-11-19467.8
2026-11-18474.2
2026-11-17472.8
2026-11-16480.2
2026-11-13474.2
2026-11-12487
2026-11-11485.6
2026-11-10480.2
2026-11-09496.6
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company is in strategic partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.